CLASS II ONGOING Drug recall · Reported 30 Jul 2025 · FDA Enforcement Report

Budesonide Inhalation Suspension, 5mg/-dose ampules per, five recalled

Cipla USA is recalling Budesonide Inhalation Suspension, 5mg/-dose ampules per, five per, distributed nationwide in the US. The recall was initiated on 30 Jun 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesBatch # 4IA0505, Exp 09/31/2026
NDC69097-318, 69097-319, 69097-321
Quantity recalled13,680 ampoules

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0541-2025
FDA event ID
97170
Recalling firm
Cipla USA, Warren, NJ
Manufacturer
Cipla USA Inc.
Classification
Class II
Status
Ongoing
Recall initiated
30 Jun 2025
FDA classified
22 Jul 2025
Reported
30 Jul 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Sterility

Timeline

30 Jun 2025Recall initiated by company
22 Jul 2025Classified by FDA+22 days
30 Jul 2025Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

Budesonide Inhalation Suspension, 0.5mg/2ml, 30 single-dose ampules per carton, five per pouch, RX Only, Manufactured by: Cipla Ltd. Indore SEZ, Pithampur, India. Manufactured for: Ciple USA, Inc. 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC# 69097-319-86 (pouch), 69097-319-87 (carton)

Where it was distributed

Distributed Nationwide in the USA

Nationwide

Questions about this recall

Is Budesonide Inhalation Suspension, 5mg/-dose ampules per, five per recalled?

Yes. Cipla USA recalled Budesonide Inhalation Suspension, 5mg/-dose ampules per, five per on 30 Jun 2025. The recall is Class II and its status is Ongoing. Recall number D-0541-2025.

Why was it recalled?

Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.

Which lots are affected?

Batch # 4IA0505, Exp 09/31/2026

Where was it sold?

Distributed Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Cipla USA

All 23

Other Budesonide recalls

All 9